Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Marts 2023

Genmab — Marts 2023

Planlagt Fastgjort Låst Flyttet Genmab
499 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • R Offline
    R Offline
    Riis7
    wrote on sidst redigeret af
    #477

    Link Preview Image
    Dansk topledelse får aktieenheder for 77 millioner

    favicon

    Euroinvestor (www.euroinvestor.dk)

    1 Reply Last reply
    0
    • P Offline
      P Offline
      Pensionisten
      wrote on sidst redigeret af
      #478

      @Riis7. Jeg har ikke plads til flere Novo i pensionsdepoterne. Og de har ligget der, stille og roligt, i mange år 😉

      1 Reply Last reply
      0
      • R Offline
        R Offline
        Riis7
        wrote on sidst redigeret af
        #479

        Sådan , nok mange dansker der har det problem:-)

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #480

          Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 https://www.biospace.com/article/releases/bolt-biotherapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-business-update/

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #481

            Collaborations with Genmab and Innovent developing next-generation Boltbody ISACs continue to progress. Both collaborations are exploring proprietary linker-payloads from the Boltbody ISAC platform, combining with Genmab’s proprietary bispecific
            antibodies

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #482

              The collaboration with Genmab exploring Boltbody ISACs using Genmab’s proprietary bispecific antibodies accounted for $4.2 million in revenue for 2022

              1 Reply Last reply
              0
              • L Offline
                L Offline
                lahn1
                wrote on sidst redigeret af
                #483

                BOLT også ude med vag PR på deres HER2 ISAC https://investors.boltbio.com/news-releases/news-release-details/bolt-biotherapeutics-announces-positive-topline-data-bdc-1001

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  Sukkeralf
                  wrote on sidst redigeret af
                  #484

                  Måske vag fordi de skal præsentere data senere?

                  1 Reply Last reply
                  0
                  • L Offline
                    L Offline
                    lahn1
                    wrote on sidst redigeret af
                    #485

                    Ja måske 🙂

                    1 Reply Last reply
                    0
                    • P Offline
                      P Offline
                      Pensionisten
                      wrote on sidst redigeret af
                      #486

                      Den optur, der startede 10. marts synes sat lidt på pause. Håber på lidt positivt nyt, der kan give fornyede kræfter.

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #487

                        interesting, a new Epcoritamab trial +Venetoclax by the Haemato Oncology Foundation in the Netherlands, with Nordic & German CLL Study Groups, don't see genmab or abbvie - Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL (AETHER) https://clinicaltrials.gov/ct2/show/NCT05791409

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #488

                          Amivantamab efficacy in pretreated NSCLC with EGFR Exon 20 insertion mutations persists long term https://dailyreporter.esmo.org/european-lung-cancer-congress-2023/elcc-2023/amivantamab-efficacy-in-pretreated-nsclc-with-egfr-exon-20-insertion-mutations-persists-long-term

                          1 Reply Last reply
                          0
                          • SolsenS Offline
                            SolsenS Offline
                            Solsen
                            wrote on sidst redigeret af
                            #489

                            Rigtig spændende med combi med venetoclax, som er et fantastisk stof. Det kan der komme noget stort ud af for Genmab/Abbvie og patienterne.

                            1 Reply Last reply
                            0
                            • StockBullS Offline
                              StockBullS Offline
                              StockBull
                              wrote on sidst redigeret af
                              #490

                              Det er i vores mørkeste øjeblikke, at vi skal fokusere for at se lyset.

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #491

                                Venetoclax is also from AbbVie if i am not mistaken...

                                1 Reply Last reply
                                0
                                • SolsenS Offline
                                  SolsenS Offline
                                  Solsen
                                  wrote on sidst redigeret af
                                  #492

                                  Correct

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    Sukkeralf
                                    wrote on sidst redigeret af
                                    #493

                                    In partnership with Roche/Genentech though

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #494

                                      https://twitter.com/tnewsomdavis/status/1641480986746662913 "Very surprised that 1/3 of audience opted
                                      for 1L Amivantamab"

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #495

                                        Daratumumab, an anti-CD38 effective in two cases of severe refractory myositis https://www.institut-myologie.org/en/2023/03/30/daratumumab-an-anti-cd38-effective-in-two-cases-of-severe-refractory-myositis/

                                        1 Reply Last reply
                                        0
                                        • StockBullS Offline
                                          StockBullS Offline
                                          StockBull
                                          wrote on sidst redigeret af
                                          #496

                                          Morn, Fibonacci købssignal https://www.proinvestor.com/boards/111776/

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper